A Clinical Study to Evaluate CAD-1883 in Essential Tremor

Summary

This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented severity of tremor based on the clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.

Timeline

Start

2019-01-23

Primary completion

2019-09-10

Completion

2019-09-24

Drugs

Indications